<!–themify_builder_static–><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span></p>
<p>Kamlesh Yadav, Ph.D., associate instructional professor (in collaboration with researchers at Icahn School of Medicine at Mount Sinai School of Medicine) published a research article titled Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer that suggest pelvic inflammation exacerbates progression of prostate cancer.</p>
<p>The study reports a significant association of pelvic inflammation with prostate cancer aggressiveness in a large cohort of men undergoing robot-assisted laparoscopic prostatectomy for localized prostate cancer. In addition, prostate cancer patients with pelvic inflammation had elevated expression of inflammation-associated genes and cancer-driving pathways in their tumors. Likewise, increased systemic inflammation with activation of the IL6-STAT pathway was seen in prostate cancer patients with pelvic inflammation. The presence of pelvic inflammation in prostate cancer patients suggests aggressive disease with a potential to develop biochemical recurrence and metastasis.</p>
<p>While the impact of pelvic inflammation on prostate cancer biology and aggressive phenotype has never been studied, the objective of the research study was to evaluate the role of pelvic inflammation on prostate cancer aggressiveness and its association with clinical outcomes in patients following radical prostatectomy.</p>
<p>“The study was conducted on a retrospective single-institutional consecutive cohort of 2278 patients who underwent robot-assisted laparoscopic prostatectomy between 01/2013 and 10/2019,” said Yadav, “where data from 2085 patients were analyzed to study the association between pelvic inflammation and adverse pathology at resection.”</p>
<p>In a subset of 1997 patients, the association between pelvic inflammation and biochemical recurrence was studied. Alteration in tumor transcriptome and inflammatory markers in patients with and without pelvic inflammation were studied using microarray analysis, immunohistochemistry, and culture supernatants derived from inflamed sites used in functional assays. Changes in blood inflammatory markers in the study cohort were analyzed by O-link. In univariate analyses, pelvic inflammation emerged as a significant predictor of adverse pathology. Pelvic inflammation exacerbates the progression of prostate cancer and drives an aggressive phenotype.</p>
<p>“This study is highly relevant,” said Yadav, “as it allows us to follow prostate cancer patients with pelvic inflammation for metastasis closely.” Still, the research findings suggest that inhibiting the STAT-IL6 pathway would benefit these patients.</p>
<p><!–/themify_builder_static–>
Kamlesh Yadav, Ph.D., associate instructional professor (in collaboration with researchers at Icahn School of Medicine at Mount Sinai School of Medicine) published a research article titled Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer that suggest pelvic inflammation exacerbates progression of prostate cancer.
The study reports a significant association of pelvic inflammation with prostate cancer aggressiveness in a large cohort of men undergoing robot-assisted laparoscopic prostatectomy for localized prostate cancer. In addition, prostate cancer patients with pelvic inflammation had elevated expression of inflammation-associated genes and cancer-driving pathways in their tumors. Likewise, increased systemic inflammation with activation of the IL6-STAT pathway was seen in prostate cancer patients with pelvic inflammation. The presence of pelvic inflammation in prostate cancer patients suggests aggressive disease with a potential to develop biochemical recurrence and metastasis.
While the impact of pelvic inflammation on prostate cancer biology and aggressive phenotype has never been studied, the objective of the research study was to evaluate the role of pelvic inflammation on prostate cancer aggressiveness and its association with clinical outcomes in patients following radical prostatectomy.
“The study was conducted on a retrospective single-institutional consecutive cohort of 2278 patients who underwent robot-assisted laparoscopic prostatectomy between 01/2013 and 10/2019,” said Yadav, “where data from 2085 patients were analyzed to study the association between pelvic inflammation and adverse pathology at resection.”
In a subset of 1997 patients, the association between pelvic inflammation and biochemical recurrence was studied. Alteration in tumor transcriptome and inflammatory markers in patients with and without pelvic inflammation were studied using microarray analysis, immunohistochemistry, and culture supernatants derived from inflamed sites used in functional assays. Changes in blood inflammatory markers in the study cohort were analyzed by O-link. In univariate analyses, pelvic inflammation emerged as a significant predictor of adverse pathology. Pelvic inflammation exacerbates the progression of prostate cancer and drives an aggressive phenotype.
“This study is highly relevant,” said Yadav, “as it allows us to follow prostate cancer patients with pelvic inflammation for metastasis closely.” Still, the research findings suggest that inhibiting the STAT-IL6 pathway would benefit these patients.